Approval Date: Mar 2023
Indicated for the acute treatment of migraine with or without aura
Approval Date: Mar 2023
Indicated for the short term management of mild to moderate acute pain
Approval Date: Feb 2023
Indicated for the treatment of partial-onset or primary generalized tonic-clonic seizures, adjunctive therapy for partial-onset, primary generalized tonic-clonic seizures, seizures associated with Lennox-Gastaut syndrome (LGS), and preventive treatment of migraine
Approval Date: Feb 2023
Temporarily relieves minor aches and pains due to headache, toothache, backache, menstrual cramps, muscular aches, minor pain of arthritis
Approval Date: Jan 2023
Indicated for the treatment of Alzheimer’s in patients with mild cognitive impairment or mild dementia sage of the disease
Approval Date: Dec 2022
In combination with other antiretrovirals, this drugs is indicated for treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug resistant HIV-1 infection
Approval Date: Dec 2022
Indicated for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, and plaque psoriasis
Approval Date: Nov 2022
A first-in-class medication, this drug is indicated to delay the onset of Stage 3 type 1 diabetes, potentially delaying the clinical diagnosis of type 1 diabetes to provide patients with months to years without the burdens of disease.
Approval Date: Sep 2022
Indicated to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations
Approval Date: Sep 2022
Indicated for the topical treatment of plaque psoriasis of up to 20% body surface area involvement